The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | 4-year update of MURANO: venR shows sustained PFS and OS benefits versus BR
John Seymour, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, presents a 4-year update of the MURANO study (NCT02005471) which has shown durable responses in patients treated with venetoclax and rituximab (venR) compared to bendamustine and rixutimab (BR). Prof. Seymour discusses an analysis of retreatment as well. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
